Session Information
Date: Monday, October 8, 2018
Session Title: Parkinson's Disease: Cognition
Session Time: 1:15pm-2:45pm
Location: Hall 3FG
Objective: We attempted to analyze the correlation between dementia and internal medicine furthermore by elucidating the relevance to the frequently administered combination of antiparkinson drug.
Background: Dementia has now been noticed as a significant non-motor symptom of Parkinson’s disease (PD). We have indicated that L-dopa formulation was speculated to have frequently administered to patients who progressed dementia, however administration of dopamine receptor agonist indicated the contrary result.
Methods: The Ministry of Health, Labour and Welfare (MHLW) of Japan has funded research programs to investigate etiology and treatment of intractable neurodegenerative diseases. PD patients in Hoehn & Yahr Stage 3-5 are registered in this program and are annually evaluated by their attending physician. There were 294183 patients from who were registered between 2010 to 2014 for PD. Ten most frequently administered combinations of antiparkinson drugs (L-dopa formulation, dopamine agonist, seregiline, amantadine, droxidopa, anticholinergic agents) was selected. Patients diagnosed PD leastwise for one year, and not having dementia at the first evaluation were included. Cox regression analysis was performed and a Kaplan-Meier curve was executed between the occurrence of dementia and the frequent combination of administered medicine. The similar analysis was performed separately among each patient group of Hoehn & Yahr Stage 3, 4 and 5.
Results: The hazard ratio against ‘single L-dopa formulation group’ was lowest (HR:0.57 95% confidence interval, 0.48 to 0.68) in the combination group of L-dopa formulation, dopamine agonist, amantadine and seregiline. It was low in the same combination group among Hoehn & Yahr Stage 3 and 4 but not in Stage 5.
Conclusions: The results indicated that combinational pharmaceutical treatment for PD may decline cognitive dysfunctionin older and less severe patients.
To cite this abstract in AMA style:
K. Konaka, Y. Kajiyama, R. Gajanan, M. Mihara, N. Hattori, H. Mochizuki. Selection of antiparkinson drug and cognition in Japanese Parkinson Disease patients [abstract]. Mov Disord. 2018; 33 (suppl 2). https://www.mdsabstracts.org/abstract/selection-of-antiparkinson-drug-and-cognition-in-japanese-parkinson-disease-patients/. Accessed June 15, 2025.« Back to 2018 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/selection-of-antiparkinson-drug-and-cognition-in-japanese-parkinson-disease-patients/